Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.05
TMO's Cash to Debt is ranked lower than
96% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. TMO: 0.05 )
Ranked among companies with meaningful Cash to Debt only.
TMO' s Cash to Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.47 Max: 2.13
Current: 0.05
0.04
2.13
Equity to Asset 0.47
TMO's Equity to Asset is ranked lower than
68% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TMO: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
TMO' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.56 Max: 0.75
Current: 0.47
0.36
0.75
Interest Coverage 5.22
TMO's Interest Coverage is ranked lower than
80% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. TMO: 5.22 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 5.22  Med: 6.56 Max: 14.24
Current: 5.22
5.22
14.24
F-Score: 8
Z-Score: 2.18
M-Score: -2.48
WACC vs ROIC
8.75%
6.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 13.40
TMO's Operating margin (%) is ranked higher than
78% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. TMO: 13.40 )
Ranked among companies with meaningful Operating margin (%) only.
TMO' s Operating margin (%) Range Over the Past 10 Years
Min: 10  Med: 11.78 Max: 14.82
Current: 13.4
10
14.82
Net-margin (%) 11.06
TMO's Net-margin (%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. TMO: 11.06 )
Ranked among companies with meaningful Net-margin (%) only.
TMO' s Net-margin (%) Range Over the Past 10 Years
Min: 7.81  Med: 9.77 Max: 11.64
Current: 11.06
7.81
11.64
ROE (%) 9.47
TMO's ROE (%) is ranked higher than
66% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. TMO: 9.47 )
Ranked among companies with meaningful ROE (%) only.
TMO' s ROE (%) Range Over the Past 10 Years
Min: 5.36  Med: 7.8 Max: 10.13
Current: 9.47
5.36
10.13
ROA (%) 4.60
TMO's ROA (%) is ranked higher than
67% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. TMO: 4.60 )
Ranked among companies with meaningful ROA (%) only.
TMO' s ROA (%) Range Over the Past 10 Years
Min: 3.58  Med: 4.65 Max: 5.52
Current: 4.6
3.58
5.52
ROC (Joel Greenblatt) (%) 48.38
TMO's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. TMO: 48.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TMO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 37.47  Med: 42.04 Max: 62.88
Current: 48.38
37.47
62.88
Revenue Growth (3Y)(%) 8.70
TMO's Revenue Growth (3Y)(%) is ranked higher than
68% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. TMO: 8.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TMO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.9  Med: 8.7 Max: 18.7
Current: 8.7
-12.9
18.7
EBITDA Growth (3Y)(%) 14.90
TMO's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. TMO: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TMO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: 14.3 Max: 40.9
Current: 14.9
-30.1
40.9
EPS Growth (3Y)(%) 13.40
TMO's EPS Growth (3Y)(%) is ranked higher than
74% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. TMO: 13.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TMO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.4  Med: 12.9 Max: 74.6
Current: 13.4
-33.4
74.6
GuruFocus has detected 6 Warning Signs with Thermo Fisher Scientific Inc $TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TMO Guru Trades in Q1 2016

Diamond Hill Capital 580,922 sh (New)
David Dreman 10,137 sh (New)
Joel Greenblatt 4,687 sh (New)
Mario Gabelli 32,720 sh (+102.41%)
Vanguard Health Care Fund 4,315,800 sh (+40.08%)
Manning & Napier Advisors, Inc 687,890 sh (+17.49%)
Pioneer Investments 2,353,745 sh (+4.94%)
PRIMECAP Management 5,439,360 sh (+0.73%)
First Eagle Investment 200 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 141,000 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Scott Black 13,031 sh (-2.23%)
Mairs and Power 1,683 sh (-3.00%)
Dodge & Cox 550,892 sh (-3.67%)
First Pacific Advisors 1,689,060 sh (-7.82%)
Steven Romick 1,507,820 sh (-7.96%)
John Rogers 540,015 sh (-11.62%)
Ken Fisher 1,642 sh (-12.05%)
Signature Select Canadian Fund 86,200 sh (-17.75%)
Larry Robbins 3,610,552 sh (-39.15%)
» More
Q2 2016

TMO Guru Trades in Q2 2016

Ray Dalio 12,466 sh (New)
Paul Tudor Jones 3,600 sh (New)
Pioneer Investments 2,593,804 sh (+10.20%)
Mairs and Power 1,786 sh (+6.12%)
First Pacific Advisors 1,788,830 sh (+5.91%)
Vanguard Health Care Fund 4,315,800 sh (unchged)
First Eagle Investment 200 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 141,000 sh (unchged)
Ken Fisher Sold Out
Scott Black Sold Out
Mario Gabelli 32,545 sh (-0.53%)
John Rogers 536,549 sh (-0.64%)
Diamond Hill Capital 574,065 sh (-1.18%)
PRIMECAP Management 5,362,400 sh (-1.41%)
David Dreman 9,811 sh (-3.22%)
Dodge & Cox 526,642 sh (-4.40%)
Steven Romick 1,415,820 sh (-6.10%)
Manning & Napier Advisors, Inc 631,340 sh (-8.22%)
Larry Robbins 2,858,240 sh (-20.84%)
Joel Greenblatt 1,790 sh (-61.81%)
» More
Q3 2016

TMO Guru Trades in Q3 2016

Ken Fisher 1,482 sh (New)
Pioneer Investments 2,645,237 sh (+1.98%)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (+64.08%)
First Eagle Investment 200 sh (unchged)
Joel Greenblatt Sold Out
John Rogers 526,143 sh (-1.94%)
PRIMECAP Management 5,204,870 sh (-2.94%)
Diamond Hill Capital 551,677 sh (-3.90%)
David Dreman 9,343 sh (-4.77%)
Vanguard Health Care Fund 4,097,300 sh (-5.06%)
Mairs and Power 1,683 sh (-5.77%)
Larry Robbins 2,686,316 sh (-6.02%)
First Pacific Advisors 1,676,150 sh (-6.30%)
Steven Romick 1,306,510 sh (-7.72%)
Ray Dalio 10,600 sh (-14.97%)
Mario Gabelli 27,345 sh (-15.98%)
Signature Select Canadian Fund 72,350 sh (-16.07%)
Paul Tudor Jones 3,000 sh (-16.67%)
Manning & Napier Advisors, Inc 413,541 sh (-34.50%)
Dodge & Cox 67,602 sh (-87.16%)
» More
Q4 2016

TMO Guru Trades in Q4 2016

Jim Simons 813,644 sh (New)
Wallace Weitz 132,160 sh (New)
Steven Cohen 183,552 sh (New)
Caxton Associates 40,000 sh (New)
Ray Dalio 28,700 sh (+170.75%)
Larry Robbins 3,659,734 sh (+36.24%)
Diamond Hill Capital 647,502 sh (+17.37%)
Ken Fisher 1,707 sh (+15.18%)
Mario Gabelli 29,220 sh (+6.86%)
PRIMECAP Management 5,304,730 sh (+1.92%)
Manning & Napier Advisors, Inc 415,211 sh (+0.40%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
David Dreman 8,862 sh (-5.15%)
Vanguard Health Care Fund 3,884,800 sh (-5.19%)
John Rogers 483,526 sh (-8.10%)
First Pacific Advisors 1,460,100 sh (-12.89%)
Steven Romick 1,134,900 sh (-13.13%)
Paul Tudor Jones 2,500 sh (-16.67%)
Pioneer Investments 2,185,073 sh (-17.40%)
Dodge & Cox 50,002 sh (-26.03%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541380    SIC: 3826
Compare:NYSE:Q, NYSE:A, NYSE:LH, NYSE:DGX, NAS:IDXX, OTCPK:SSMXY, NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NAS:BRKR, NYSE:CRL, NAS:PRAH, NAS:VWR, NYSE:ALR, NAS:PRXL, OTCPK:CZMWY, NAS:INCR » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland,
Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Thermo Fisher Scientific Inc is a Delaware corporation and was incorporated in 1956. The Company completed its initial public offering in 1967 and was listed on the New York Stock Exchange in 1980. In November 2006, Thermo Electron Corporation merged with Fisher Scientific International Inc. to create Thermo Fisher. The Company completed its initial public offering in 1967. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It serves customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings. The Company's continuing operations fall into three business segments: Analytical Technologies, Specialty Diagnostics, and Laboratory Products and Services. Analytical Technologies segment provides offerings of instruments, reagents, consumables, software and services that are used for applications in the laboratory, on the production line and in the field. These products are used by customers in all four of the company's key end markets: healthcare and diagnostics; pharmaceutical and biotechnology; academic and government; and industrial and applied. This segment includes four primary businesses - Chromatography and Mass Spectrometry, Chemical Analysis, Environmental and Process Instruments, and Biosciences. Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. Its chemical analysis products fall into three main categories: materials and minerals; molecular spectroscopy; and portable analytical instruments. Customers use these products to quickly and accurately analyze the composition of materials in small samples to optimize workflows in academic, life sciences, pharmaceutical, and industrial applications. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Services segment provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory. The Company serves their customers through four brands, Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services. The Company markets and sells its products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors and various catalogs. It encounters aggressive and able competition in virtually all of the markets it serves. It is subject to various laws and

Guru Investment Theses on Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific - Jan 26, 2017

Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

John Rogers Comments on Thermo Fisher Scientific Inc. - Jan 20, 2017

Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific Guru stock highlight
Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation. Read more...
John Rogers Comments on Thermo Fisher Scientific Inc. Guru stock highlight
Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track. Read more...
5 Stocks Hit 52-Week High Prices Thermo Fisher and Goldman Sachs among companies with rising prices
According to GuruFocus' list of 52-week highs, these guru stocks have reached their historical high prices. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.17
TMO's P/E(ttm) is ranked higher than
52% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.58 vs. TMO: 31.17 )
Ranked among companies with meaningful P/E(ttm) only.
TMO' s P/E(ttm) Range Over the Past 10 Years
Min: 12.67  Med: 26.52 Max: 62.79
Current: 31.17
12.67
62.79
Forward P/E 17.39
TMO's Forward P/E is ranked higher than
73% of the 45 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. TMO: 17.39 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.17
TMO's PE(NRI) is ranked higher than
52% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.65 vs. TMO: 31.17 )
Ranked among companies with meaningful PE(NRI) only.
TMO' s PE(NRI) Range Over the Past 10 Years
Min: 13.48  Med: 26.58 Max: 62.07
Current: 31.17
13.48
62.07
Price/Owner Earnings (ttm) 23.74
TMO's Price/Owner Earnings (ttm) is ranked higher than
64% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.11 vs. TMO: 23.74 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TMO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.21  Med: 19.16 Max: 74.79
Current: 23.74
9.21
74.79
P/B 2.91
TMO's P/B is ranked higher than
63% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. TMO: 2.91 )
Ranked among companies with meaningful P/B only.
TMO' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 1.6 Max: 2.95
Current: 2.91
0.83
2.95
P/S 3.45
TMO's P/S is ranked higher than
50% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. TMO: 3.45 )
Ranked among companies with meaningful P/S only.
TMO' s P/S Range Over the Past 10 Years
Min: 1.25  Med: 2.3 Max: 3.61
Current: 3.45
1.25
3.61
PFCF 23.23
TMO's PFCF is ranked higher than
55% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.89 vs. TMO: 23.23 )
Ranked among companies with meaningful PFCF only.
TMO' s PFCF Range Over the Past 10 Years
Min: 10.23  Med: 20.17 Max: 31.02
Current: 23.23
10.23
31.02
POCF 19.96
TMO's POCF is ranked lower than
57% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.57 vs. TMO: 19.96 )
Ranked among companies with meaningful POCF only.
TMO' s POCF Range Over the Past 10 Years
Min: 8.74  Med: 17.26 Max: 25.65
Current: 19.96
8.74
25.65
EV-to-EBIT 31.49
TMO's EV-to-EBIT is ranked lower than
67% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.83 vs. TMO: 31.49 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.9  Med: 22.5 Max: 64.9
Current: 31.49
10.9
64.9
EV-to-EBITDA 18.47
TMO's EV-to-EBITDA is ranked lower than
54% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.07 vs. TMO: 18.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.1 Max: 32.6
Current: 18.47
6.8
32.6
PEG 2.14
TMO's PEG is ranked higher than
74% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. TMO: 2.14 )
Ranked among companies with meaningful PEG only.
TMO' s PEG Range Over the Past 10 Years
Min: 0.55  Med: 2.17 Max: 7.85
Current: 2.14
0.55
7.85
Shiller P/E 45.14
TMO's Shiller P/E is ranked lower than
62% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.88 vs. TMO: 45.14 )
Ranked among companies with meaningful Shiller P/E only.
TMO' s Shiller P/E Range Over the Past 10 Years
Min: 20.78  Med: 39.23 Max: 62.45
Current: 45.14
20.78
62.45
Current Ratio 1.45
TMO's Current Ratio is ranked lower than
78% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. TMO: 1.45 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.18 Max: 3.83
Current: 1.45
1.22
3.83
Quick Ratio 0.99
TMO's Quick Ratio is ranked lower than
83% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. TMO: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.61 Max: 3.4
Current: 0.99
0.87
3.4
Days Inventory 80.91
TMO's Days Inventory is ranked higher than
51% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.66 vs. TMO: 80.91 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 81.13
Current: 80.91
65.13
81.13
Days Sales Outstanding 60.89
TMO's Days Sales Outstanding is ranked higher than
57% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.91 vs. TMO: 60.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 60.89
Current: 60.89
50.89
60.89
Days Payable 35.16
TMO's Days Payable is ranked lower than
65% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.58 vs. TMO: 35.16 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.45 Max: 41.58
Current: 35.16
31.3
41.58

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.38
TMO's Dividend Yield is ranked lower than
88% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. TMO: 0.38 )
Ranked among companies with meaningful Dividend Yield only.
TMO' s Dividend Yield Range Over the Past 10 Years
Min: 0.22  Med: 0.48 Max: 0.86
Current: 0.38
0.22
0.86
Dividend Payout 0.12
TMO's Dividend Payout is ranked higher than
91% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. TMO: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
TMO' s Dividend Payout Range Over the Past 10 Years
Min: 0.12  Med: 0.13 Max: 0.17
Current: 0.12
0.12
0.17
Forward Dividend Yield 0.38
TMO's Forward Dividend Yield is ranked lower than
89% of the 87 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.13 vs. TMO: 0.38 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.38
TMO's Yield on cost (5-Year) is ranked lower than
92% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.65 vs. TMO: 0.38 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TMO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.22  Med: 0.48 Max: 0.86
Current: 0.38
0.22
0.86
3-Year Average Share Buyback Ratio -3.00
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. TMO: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -1.3 Max: 4.4
Current: -3
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.38
TMO's Price/Projected FCF is ranked higher than
68% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. TMO: 1.38 )
Ranked among companies with meaningful Price/Projected FCF only.
TMO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.23 Max: 14.42
Current: 1.38
0.65
14.42
Price/DCF (Earnings Based) 1.36
TMO's Price/DCF (Earnings Based) is ranked higher than
69% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.71 vs. TMO: 1.36 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.50
TMO's Price/Median PS Value is ranked lower than
82% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.06 vs. TMO: 1.50 )
Ranked among companies with meaningful Price/Median PS Value only.
TMO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 0.91 Max: 1.5
Current: 1.5
0.36
1.5
Price/Peter Lynch Fair Value 2.15
TMO's Price/Peter Lynch Fair Value is ranked higher than
57% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.42 vs. TMO: 2.15 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TMO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.61  Med: 1.71 Max: 2.64
Current: 2.15
0.61
2.64
Earnings Yield (Greenblatt) (%) 3.20
TMO's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 226 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. TMO: 3.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TMO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 4.4 Max: 9.1
Current: 3.2
1.5
9.1
Forward Rate of Return (Yacktman) (%) 17.96
TMO's Forward Rate of Return (Yacktman) (%) is ranked higher than
79% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. TMO: 17.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TMO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 8.1  Med: 18.4 Max: 33
Current: 17.96
8.1
33

More Statistics

Revenue (TTM) (Mil) $18,274
EPS (TTM) $ 5.09
Beta1.01
Short Percentage of Float1.21%
52-Week Range $127.56 - 160.68
Shares Outstanding (Mil)395.03

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,566 20,409 21,085
EPS ($) 8.35 8.26 10.99
EPS w/o NRI ($) 8.35 8.26 10.99
EPS Growth Rate
(3Y to 5Y Estimate)
10.73%
Dividends Per Share ($) 0.63 0.69 0.77
» More Articles for TMO

Headlines

Articles On GuruFocus.com
Weitz Funds Comments on Thermo Fisher Scientific Jan 26 2017 
John Rogers Comments on Thermo Fisher Scientific Inc. Jan 20 2017 
John Rogers' Ariel Appreciation Fund 4th Quarter Commentary Jan 20 2017 
8 Best Stocks for Value Investors Dec 10 2016 
A Quick Review of Thermo Fisher Dec 07 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
5 Stocks Hit 52-Week High Prices Jul 11 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 

More From Other Websites
Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc. Feb 14 2017
Thermo Fisher Scientific Receives Early Termination of Hart-Scott-Rodino Waiting Period for... Feb 13 2017
Weitz Investment Looks to Visa (V), Amazon (AMZN), Others for Big Returns After Subpar 2016 Feb 07 2017
Why the state's two biggest medical device firms have gained $4.5B in market cap this week Feb 02 2017
The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American... Feb 02 2017
Final Trade: DIS, GOOGL & more Feb 01 2017
Top Research Reports for February 1, 2017 Feb 01 2017
The Hot Stock: Thermo Fisher Scientific Jumps 6.4% Jan 31 2017
Edited Transcript of TMO earnings conference call or presentation 31-Jan-17 1:30pm GMT Jan 31 2017
Thermo Fisher Scientific, Inc. : TMO-US: Dividend Analysis : December 15th, 2016 (record date) : By... Jan 31 2017
Thermo Fisher CEO Says M&A Funnel Is 'Pretty Full' Jan 31 2017
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat Jan 31 2017
Thermo Fisher (TMO): Tops Q4 Earnings, Misses Revenues Jan 31 2017
THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 31 2017
Q4 2016 Thermo Fisher Scientific Inc Earnings Release - Before Market Open Jan 31 2017
Thermo Fisher beats 4Q profit forecasts Jan 31 2017
Thermo Fisher beats 4Q profit forecasts Jan 31 2017
Thermo Fisher quarterly profit tops Wall Street expectations Jan 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)